Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

LIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

REVENUES:

Sales $489,664 $428,729 $1,408,603 $1,287,802

Other revenues 8,818 9,692 25,813 34,865

498,482 438,421 1,434,416 1,322,667

COSTS AND EXPENSES:

Cost of sales 121,477 82,258 312,711 251,970

Research and development 88,325 93,527 250,169 274,078

Selling, general and

administrative 222,948 186,456 631,832 527,962

Settlement reserve 7,450 369,000 7,450 425,000

Restructuring charges 1,497 - 6,973 -

In-process research and

development - - 10,000 -

441,697 731,241 1,219,135 1,479,010

INCOME (LOSS) FROM

OPERATIONS 56,785 (292,820) 215,281 (156,343)

OTHER INCOME (EXPENSE):

Interest income 4,002 8,868 15,515 23,485

Interest expense (8,831) (5,660) (25,697) (15,272)

Gain on extinguishment of

debt - 5,319 - 5,319

Gain on sale of investment - - - 5,791

Other income (expense), net (2,284) 2,493 1,488 3,747

(7,113) 11,020 (8,694) 23,070

INCOME (LOSS) BEFORE INCOME

TAXES
'/>"/>

SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... has been granted a patent by the United ... delivery system for delivering its "original" RNAi compounds ... treatment of diseases with an inflammatory component. Potential ...
(Date:9/17/2014)... Beckman Coulter , a global leader in ... its agreement with Personify for an additional ... will continue to streamline the Beckman Coulter talent acquisition ... time-to-fill, time-to-source and a deep reduction to cost-per-hire. , ... based on the success of our partnership over the ...
(Date:9/17/2014)... 2014 First antibacterial ... a truly novel class of anti-infective in ... a biopharmaceutical company developing a truly novel ... has secured £4.0m ($6.4m) to advance the ... a range of Gram-positive infections including  Clostridium ...
(Date:9/17/2014)... 2014 The Pistoia Alliance, a ... the barriers to innovation in life sciences R&D ... Carmen Nitsche as Executive Director Business Development North ... global reach. , Carmen joins the Pistoia Alliance ... Development. At Accelrys, she managed various life sciences ...
Breaking Biology Technology:RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 2RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 3RXi Pharmaceuticals Strengthens Intellectual Property Portfolio 4Beckman Coulter Signs 3-year RPO Contract with Personify 2Beckman Coulter Signs 3-year RPO Contract with Personify 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Pistoia Alliance Expands Business Development with Appointment of Carmen Nitsche 2
... TSX symbol: SBS, CALGARY, Oct. 17 /PRNewswire-FirstCall/ ... (TSX:SBS), today announced that it has reached an,agreement ... funding for the,development of Botaneco as an independent ... a 27-month period, beginning in the fourth,quarter of ...
... KYPH ) announced today that its stockholders approved ... MDT ) at a special,meeting of stockholders held ... Kyphon entered into a,definitive merger agreement with Medtronic, pursuant ... shares of Kyphon common stock for,$71.00 per share in ...
... employed for a variety of uses including composite materials, ... proven useful for these purposes, no one really knows ... For example, how do nanotubes and chemical functional groups ... this question could lead to improvements in future nano ...
Cached Biology Technology:Botaneco obtains $2.4 million in funding from AVAC 2Botaneco obtains $2.4 million in funding from AVAC 3Kyphon Stockholders Approve Merger with Medtronic 2Researchers measure carbon nanotube interaction 2
(Date:9/17/2014)... complex social behavior by studying nonhuman mammals and primates, ... With their unusually large brains relative to their body ... social environment---not merely in a large population of cooperating ... dynamic setting of alliances and competitors. The same is ... and social carnivores, like hyenas and lions. , A ...
(Date:9/16/2014)... NEW YORK (17 September, 2014)More than $100 trillion ... megatons of annual carbon dioxide (CO2)a 40 percent ... by 2050 if the world expands public transportation, ... new report released by the University of California, ... Policy (ITDP). , Further, an estimated 1.4 ...
(Date:9/16/2014)... -- Each tree species has its own bacterial identity. ... colleagues from other institutions who studied the genetic fingerprints ... a Panamanian island. , "This study demonstrates for the ... and with different ecological strategies possess very different microbial ... Kembel, a former postdoctoral researcher in the UO,s Institute ...
Breaking Biology News(10 mins):Being social: Learning from the behavior of birds 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 2Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 3Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 4Global shift away from cars saves US$100 trillion, eliminates 1,700 MT of CO2 pollution 5Microbiome research shows each tree species has a unique bacterial identity 2
... MADISON, WI, OCTOBER 12, 2009 Areas of ... and recreational (not grazing) purposes, i.e. "urban grasslands" are ... are over 150,000 km2of urban grasslands in the U.S. ... about nutrient runoff to streams, lakes, and estuaries and ...
... by a research group at the Sahlgrenska Academy at the ... of glandular cancer usually in the head and neck and ... to quicker and better diagnosis and more effective treatment. ... Proceedings of the National Academy of Sciences (PNAS). ...
... graphene more useful in electronics applications, Kansas State University ... graphene. Vikas Berry is a K-State assistant professor ... material only a single atom thick and discovered just ... thus controlling its electronics properties -- Berry and Kabeer ...
Cached Biology News:Nitrogen mysteries in urban grasslands 2Nitrogen mysteries in urban grasslands 3New cancer gene discovered 224-carat gold 'snowflakes' improve graphene's electrical properties 2
...
...
...
... Weight DNA Markers are suitable for sizing linear ... low-percentage agarose gels. The 13 bands consist of ... digests of Lambda DNA (cIind1ts857 Sam7). Ethidium bromide ... asterisk (8271 bp 8612 bp 12220 bp and ...
Biology Products: